Zogenix, Inc. (NASDAQ:ZGNX) is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.98 per share.
For the full year, analysts predict revenues of $ 13.36 million, while looking forward to loss of $ 3.54 per share.
Previous Quarter Performance
Zogenix, Inc. reported loss for the second quarter of $ 0.96 per share, from the revenue of $ 1.03 million. Wall street analysts are predicting, loss of $ 1.00 per share. The bottom line results beat street analysts by $ 0.04 or 4.00 percent.
Stock Performance
On Friday, shares of Zogenix, Inc. has traded high as $ 21.79 and has cracked $ 21.17 on the downward trend, reaching $ 21.45 with volume of 846.20 thousand shares.
According to the previous trading day, closing price of $ 21.45, representing a 29.79 % increase from the 52 week low of $ 16.65 and a 62.23 % decrease over the 52 week high of $ 57.22.
The company has a market capital of $ 1.19 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Zogenix, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.zogenix.com
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc.
